U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H28N2O3.ClH
Molecular Weight 380.909
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYPHENCYCLIMINE HYDROCHLORIDE

SMILES

Cl.CN1CCCN=C1COC(=O)C(O)(C2CCCCC2)C3=CC=CC=C3

InChI

InChIKey=WXAYTPABEADAAB-UHFFFAOYSA-N
InChI=1S/C20H28N2O3.ClH/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17;/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula C20H28N2O3
Molecular Weight 344.4479
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers. Daricon was discontinued in USA, but still used worldwide.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DARICON

Approved Use

Oxyphencyclimine binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Oxphencyclimine inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach.
Doses

Doses

DosePopulationAdverse events​
20 mg single, oral
Highest studied dose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources: Page: p.13
unhealthy
n = 5
Health Status: unhealthy
Condition: Peptic ulcer
Population Size: 5
Sources: Page: p.13
10 mg 3 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Peptic ulcer
Sources:
5 mg single, intramuscular
Studied dose
Dose: 5 mg
Route: intramuscular
Route: single
Dose: 5 mg
Sources: Page: p.13
unhealthy
n = 5
Health Status: unhealthy
Condition: Peptic ulcer
Population Size: 5
Sources: Page: p.13
PubMed

PubMed

TitleDatePubMed
A LONG ACTING ANTICHOLINERGIC-SEDATIVE COMBINATION IN GASTROINTESTINAL DISORDERS. CLINICAL TRIAL OF OXYPHENCYCLIMINE HYDROCHLORIDE WITH PHENOBARBITAL (DARICON PB).
1964 May
Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors.
1992 Sep 1
Patents

Sample Use Guides

In clinical trials oxyphencyclimine hydrochloride (5 mg) was prescribed daily, one tablet three times a day.
Route of Administration: Oral
In Vitro Use Guide
[3H]NMS binding to M4 receptor was measured at 25°C in a total volume of 1.2 ml using the following incubation buffer: 50 mM sodium phosphate (pH 7.4) enriched with 2 mM MgCI2, 1% bovine serum albumin (except when indicated) and the indicated tracer and drug concentrations. In binding experiments on rat striatum ho-mogenates, the tracer concentration was 0.25 nM and the protein concentration 30-40 ug per assay (about 50 pM binding sites). Under equilibrium conditions (2 h incubation at 25°C) [3H]NMS labelled M,. M, and M4 sites in this brain region. To analyze tracer binding to M4 sites only, striatum homogenates were preincubated for 2 h at 25°C to allow equilibrium binding, then induced tracer dissociation by adding 1 uM atropine. [3H]NMS dissociated from its binding sites after 35 min of isotopic dilution, the residual binding being about 30% of initial binding. R-enantiomer of Oxyphencyclimine displaced binding of [3H]NMS to M4 receptors with pKi of 9.2, whereas binding of its S-enantiomer was less potent.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:11:57 GMT 2023
Edited
by admin
on Fri Dec 15 16:11:57 GMT 2023
Record UNII
GWO1432WOU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYPHENCYCLIMINE HYDROCHLORIDE
JAN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
DARICON
Brand Name English
OXYPHENCYCLIMINE HYDROCHLORIDE [MI]
Common Name English
OXYPHENCYCLIMINE HYDROCHLORIDE [VANDF]
Common Name English
OXYPHENCYCLIMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
OXYPHENCYCLIMINE HYDROCHLORIDE [MART.]
Common Name English
NSC-528449
Code English
OXYPHENCYCLIMINE HCL
Common Name English
Oxyphencyclimine hydrochloride [WHO-DD]
Common Name English
(1,4,5,6-Tetrahydro-1-methyl-2-pyrimidinyl)methyl α-phenylcyclohexaneglycolate monohydrochloride
Systematic Name English
OXYPHENCYCLIMINE HYDROCHLORIDE [JAN]
Common Name English
BENZENEACETIC ACID, .ALPHA.-CYCLOHEXYL-.ALPHA.-HYDROXY-, (1,4,5,6-TETRAHYDRO-1-METHYL-2-PYRIMIDINYL)METHYL ESTER, MONOHYDROCHLORIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
NCI_THESAURUS C29698
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID6045909
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
RXCUI
91164
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY RxNorm
MESH
C100201
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
FDA UNII
GWO1432WOU
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
SMS_ID
100000085512
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
MERCK INDEX
m8342
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY Merck Index
EVMPD
SUB03594MIG
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL1495
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
PUBCHEM
66061
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
DRUG BANK
DBSALT000812
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
NSC
528449
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
ECHA (EC/EINECS)
204-742-8
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
CAS
125-52-0
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
NCI_THESAURUS
C66284
Created by admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY